1. Home
  2. Analysis
  3. Rescriptor
  4. Nausea-and-vomiting

Rescriptor and Nausea and vomiting - a phase IV clinical study of FDA data

Summary:

Nausea and vomiting is reported as a side effect among people who take Rescriptor (delavirdine mesylate), especially for people who are male, 30-39 old, have been taking the drug for 6 - 12 months also take Lamivudine, and have Hiv infection.

The phase IV clinical study analyzes which people have Nausea and vomiting when taking Rescriptor. It is created by eHealthMe based on reports of 426 people who have side effects when taking Rescriptor from the FDA, and is updated regularly.

What is Rescriptor?

Rescriptor has active ingredients of delavirdine mesylate. eHealthMe is studying from 426 Rescriptor users. Check the latest studies of Rescriptor.

What is Nausea and vomiting?

Nausea and vomiting is found to be associated with 3,703 drugs and 5,744 conditions by eHealthMe. Check the latest studies of Nausea and vomiting.

On Jul, 20, 2026

426 people reported to have side effects when taking Rescriptor.
Among them, 14 people (3.29%) have Nausea and vomiting.

Could Rescriptor cause Nausea and vomiting?

Among these 14 people:

How long have people been on Rescriptor when they have Nausea and vomiting? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 100 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Nausea and vomiting when taking Rescriptor? *

  • female: 28.57 %
  • male: 71.43 %

What is the age of people who have Nausea and vomiting when taking Rescriptor? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 7.69 %
  • 20-29: 23.08 %
  • 30-39: 30.77 %
  • 40-49: 7.69 %
  • 50-59: 7.69 %
  • 60+: 23.08 %

What are other drugs people take besides Rescriptor? *

  1. Lamivudine: 4 people, 28.57%
  2. Zovirax: 3 people, 21.43%
  3. Combivir: 3 people, 21.43%
  4. Dapsone: 3 people, 21.43%
  5. Diflucan: 3 people, 21.43%
  6. Hydroxyurea: 3 people, 21.43%
  7. Kaletra: 3 people, 21.43%
  8. Zithromax: 3 people, 21.43%
  9. Doxil: 2 people, 14.29%
  10. Didanosine: 2 people, 14.29%

What are other side effects people have besides Nausea and vomiting? *

  1. Nausea (feeling of having an urge to vomit): 6 people, 42.86%
  2. Cardiac Arrest: 4 people, 28.57%
  3. Dehydration (dryness resulting from the removal of water): 4 people, 28.57%
  4. Influenza Like Illness: 3 people, 21.43%
  5. Ventricular Tachycardia (rapid heartbeat that originates in one of the lower chambers (the ventricles) of the heart): 3 people, 21.43%
  6. Hepatitis Fulminant (life-threatening condition defined by significantly impaired liver function): 3 people, 21.43%
  7. Blood Carbon Dioxide Decreased: 2 people, 14.29%
  8. Cerebral Oedema (swelling of brain): 2 people, 14.29%
  9. Lactic Acidosis (low ph in body tissues): 2 people, 14.29%
  10. Confusion: 2 people, 14.29%

What are the existing conditions these people have? *

  1. Pneumonia: 1 person, 7.14%
  2. Hiv Infection: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Rescriptor and have Nausea and vomiting?

- Check whether Nausea and vomiting is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rescriptor:

Nausea and vomiting treatments and more:

How severe was Nausea and vomiting and when was it recovered:

Expand to all the drugs that have ingredients of delavirdine mesylate:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Rescriptor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nausea and vomiting:

Browse all the conditions that are associated with Nausea and vomiting:

How the study uses the data?

The study uses data from the FDA. It is based on delavirdine mesylate (the active ingredients of Rescriptor) and Rescriptor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.